AFMD Affimed N.V.

$AFMD Bruker is attending CTS east coast (clinical trial supply) conference. The third B2B conference in 3 weeks. Certainly a very busy schedule.

$AFMD Just found that Roche terminated their allogenic CAR-T pipeline RG6540 for BMCA. They acquired this drug from Poseida. Maybe it's the high time for them to give AFM26(RO7297089) a fair opportunity. Their bet on allogenic CAR-T cells (Poseida) looks more and more a failed attempt now. Low neural toxicity is the key for off the shelf cell therapy and I firmly believe on allogenic/cord blood NK cells together with ICE molecules can be the answer. For patents that are newly diagnosed, ICE molecules alone might be sufficient-- patient population matters!

$AFMD - ARTV: At the same time, the deaths of two patients have raised safety concerns. One patient in the biotech’s phase 2a basket trial suffered a fatal neurological event. The investigator and an independent safety review ruled that the death was likely related to fludarabine, a chemotherapy drug used in Artiva’s lymphodepletion regimen. The FDA asked Artiva to pause enrollment and dosing in the phase 2a study. Another participant died suddenly about two months after initiating treatment. The investigator ruled the death unrelated to AlloNK or any other component of the study treatment regimen. The cause of death is unknown.

$AFMD 'The combination of AFM24 and Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq) has demonstrated a well-managed safety profile with no dose-limiting toxicities or unexpected toxicities reported to date.'

$AFMD Given the recent setbacks with ARTV's AlloNK, the Affimed pipeline looks like an attractive acquisition target again!

$AFMD Gilde is not a $2.00 seller. • Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing the company with one of the most mature pipelines in the innate immune oncology field. • The company’s lead product candidate has demonstrated transformational data in patients suffering from end-stage Hodgkin’s lymphoma. • Affimed’s second product candidate has shown very promising data in end-stage lung cancer patients, a group that is rapidly growing and for which treatment options are virtually non-existent.

$AFMD I can't help but start wondering if they will ever tell us anything. This might stay as an unresolved case for decades.

$AFMD 4900% YTD Amazing c-sweet. best. ever. i wouodnt trade CEO for 1 week w Syndey Sweeny

$AFMD I looked more into this and can tell you this we won’t know till we know !! We wait for iether dagger in the chest or the holly grail !!

$AFMD The strongest unusual pattern is: The operating subsidiary entered formal liquidation, but the publicly visible outcome of the N.V. parent remains unclear, even though the parent continues to appear legally maintained. That could mean several things: the parent’s estate was too limited for an ordinary formal proceeding; the parent is being held while the GmbH assets are monetized; negotiations or a restructuring path remained unresolved; or the complete outcome simply has not been publicly indexed. I found no buyer, asset-sale disclosure, patent assignment, restructuring plan, or confirmation that existing common equity survives. So yes, something remains unexplained. But the unexplained item is the parent’s legal disposition, not proof from the trading that a revival has already been agreed. The single document most likely to resolve this would be the administrator’s report from the September 29, 2025 creditors’ meeting.

$AFMD something really interesting is that as early as of this year, there was 15.2 million shares outstanding. Now there are 16.4 million it could just be a recount as that Schwab did not take that into consideration and just did a recount, but it’s still interesting